Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $28.50 USD
Change Today +0.35 / 1.24%
Volume 299.3K
OVAS On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 5:20 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

ovascience inc (OVAS) Snapshot

Open
$27.97
Previous Close
$28.15
Day High
$29.11
Day Low
$27.48
52 Week High
03/25/15 - $55.69
52 Week Low
07/31/14 - $9.02
Market Cap
775.1M
Average Volume 10 Days
478.1K
EPS TTM
$-2.40
Shares Outstanding
27.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for OVASCIENCE INC (OVAS)

Related News

No related news articles were found.

ovascience inc (OVAS) Related Businessweek News

No Related Businessweek News Found

ovascience inc (OVAS) Details

OvaScience, Inc., a life science company, engages in the discovery, development, and commercialization of new treatments for infertility. The company’s patented technology is based on the discovery of egg precursor (EggPC) cells, which are immature egg cells found in the protective outer layer of a woman's own ovaries. It is developing and commercializing various fertility treatment options designed to enhance egg health and revolutionize in vitro fertilization (IVF) comprising AUGMENT to improve the energy and health of the woman’s eggs by using mitochondria from a woman's EggPC cells; OvaPrime treatment for boosting a woman's egg reserve by transferring the EggPCs from woman's own ovaries; OvaTure to create mature fertilizable eggs from a woman’s own EggPC cells without the need for hormone injections; and OvaXon for the prevention of genetic disease and animal health. The company was formerly known as Ovastem, Inc. and changed its name to OvaScience, Inc. in May 2011. OvaScience, Inc. was founded in 2011 and is based in Cambridge, Massachusetts.

52 Employees
Last Reported Date: 03/16/15
Founded in 2011

ovascience inc (OVAS) Top Compensated Officers

Co-Founder, Chief Executive Officer and Direc...
Total Annual Compensation: --
President and Chief Scientific Officer
Total Annual Compensation: $644.0K
Chief Commercial Officer
Total Annual Compensation: $21.1K
Compensation as of Fiscal Year 2014.

ovascience inc (OVAS) Key Developments

OvaScience Appoints Revi Mehrotra as the Chief Corporate Development Officer

OvaScience has named Revi Mehrotra as the chief corporate development officer. Mehrotra was recently global head of biotechnology equity research at Credit Suisse.

OvaScience, Inc. Appoints John Eisel as Executive Vice President of Global Site Operations, and Gabriel M. Cohn as Head of Medical Affairs and Translational Medicine

OvaScienceSM announced two new positions that support OvaScience™s expanding international operations. John Eisel has joined the Company as Executive Vice President of Global Site Operations, and Gabriel M. Cohn, M.D., has joined as Head of Medical Affairs and Translational Medicine. Mr. Eisel joins from InnerWorkings LLC, where he served as Chief Operating Officer since 2011. Prior to that, he was Divisional Vice President of Strategic Operations, Pharmacy Services for Walgreens. He also held roles of increasing responsibility at McKinsey & Company, including serving as Associate Principal. Mr. Eisel began his career at PricewaterhouseCoopers, serving as a Senior Associate in Financial Advisory Services. Dr. Cohn is a Board-certified OB/GYN and Clinical Geneticist who previously served as the Chief of the Division of Clinical and Reproductive Genetics Department at Baystate Medical Center and the Director of Reproductive Genetics, Division of Maternal Fetal Medicine at SUNY Health Science Center (HSC) at Syracuse. Dr. Cohn joins OvaScience from Shire, where he held roles that included Medical Director and Interim Medical Lead for the Gaucher Disease Franchise and the Senior Medical Director of Clinical Sciences.

OvaScience Appoints John P. Howe to the Board of Directors

OvaScience announced the appointment of John P. Howe, III, M.D., former President and Chief Executive Officer of Project HOPE, to the OvaScience Board of Directors.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OVAS:US $28.50 USD +0.35

OVAS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OVAS.
View Industry Companies
 

Industry Analysis

OVAS

Industry Average

Valuation OVAS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 49,896.8x
Price/Book 4.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 39,742.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OVASCIENCE INC, please visit www.ovascience.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.